Continual reassessment method
The continual reassessment method updates a dose-toxicity model as outcomes arrive and selects a dose near a stated target.
Why this level?
not one of the five research areas this hierarchy covers. NHMRC 2009 sourceDose selection is a feasibility and safety question, not one of the five research areas this hierarchy covers. It does not establish comparative treatment benefit.
Fit
When to use it, and when not to
Use it when
- You need to select a dose for later study under a prespecified safety plan.
- The toxicity outcome and its observation window can guide the next allocation.
Not when
- You need to choose the allocation approach first. Compare dose-finding designs. Read: Choosing a dose-finding design
- You need to establish treatment benefit against a comparator. Use a randomized trial. Read: Randomized controlled trial
Before you start
What you need
- Toxicity definition and targetDefine a dose-limiting toxicity and the full assessment window before recruitment.
- Dose levels and safety limitsFix the starting dose, allowed moves, stopping rules and independent safety oversight.
- Simulated trial scenariosVary toxicity curves, accrual and delayed harm. Check selection accuracy and exposure to unsafe doses.
- Pending toxicity is not absence of toxicity.How to check: Wait for the required window or use a validated extension designed for partial follow-up.
- The dose ordering and safety target fit the treatment.How to check: Toxicity-focused dose selection may not identify the best benefit-risk balance or biological dose.
Plain language
How it works
Set candidate doses, a target toxicity probability and a starting model before recruitment. The model links dose to toxicity and learns from observed outcomes. Select the next dose using the updated model and prespecified safety constraints. Limit jumps and define overdose stopping rules. The original method needs completed toxicity outcomes; a time-to-event extension handles partial follow-up under added assumptions.
Vary the starting dose-toxicity guesses and true toxicity curves. Examine selection accuracy, stopping and exposure to unsafe doses. A fitted model does not guarantee safe decisions when its assumptions fit poorly.
Worked example
A worked example
- Setting
- An early-phase trial follows a prespecified toxicity window.
- Question
- What do the observed counts imply under the stated design?
- Approach
- The target is 25 in 100. One of four patients has a dose-limiting toxicity; update the prespecified model with all outcomes.
- Result
- One of four patients has a toxicity: 25 in 100.
- What it means
- The observed share equals the target, but does not choose the next dose alone. The model and safety rules govern that decision.
In practice
Recent studies PubMed search · not vetted
Watch out
Common mistakes
The one to remember
The next dose depends on the full model and safety constraints, not the last cohort alone. Pending outcomes require a method that accounts for delayed toxicity.
- Equating dose selection with proof of efficacy.Instead: Selection is uncertain. Confirm benefit in a suitable later trial.
- Changing allocation rules after a worrying result.Instead: Apply the prespecified safety and stopping rules with the safety team.
Inside Mallard
How Mallard uses this
Plans do not link to this design yet. Mallard has no sample-size form for the continual reassessment method. A plan sized by simulation gets no headline sample size; Mallard does not run that simulation.
design.continual_reassessment, the id a plan cue records.How to report it
Use CONSORT-DEFINE to report the dose-selection goal, toxicity window, allocation, safety and stopping rules, deviations and participant flow. Separate observed toxicity from model estimates. State the final dose recommendation and its uncertainty. A reporting guideline is not a design manual: use it to make the study transparent, not as a substitute for careful design. Check the target journal's own requirements as well, which this page cannot know.
Related Learn pages
Related designs and methods
Evidence
Sources & further reading
- Continual reassessment method: a practical design for phase 1 clinical trials in cancer (opens in a new tab) · Biometrics
- Sequential designs for phase I clinical trials with late-onset toxicities (opens in a new tab) · Biometrics · doi 10.1111/j.0006-341x.2000.01177.x
- Enhancing reporting quality and impact of early phase dose-finding clinical trials: CONSORT Dose-finding Extension (CONSORT-DEFINE) guidance (opens in a new tab) · BMJ · doi 10.1136/bmj-2023-076387